Trial Profile
Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ARCAGY-GINECO; CHIVA; GINECO GINEGEPS
- 24 Oct 2023 Results assessing links between KELIMTM values and pathological response, and changes in TILs, in ovarian cancer patients treated with neo-adjuvant chemotherapy (NACT) +/- interval debulking surgery, presented at the 48th European Society for Medical Oncology Congress.
- 06 Jun 2023 Results (n=105) assessing the CD47 expression in ovarian cancer patients at diagnosis and after neoadjuvant chemotherapy and its relationship to other iTME features, including circulating level of thrombospondin-1 (TSP-1), presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 25 Jan 2023 Results assessing the impact of combining nintedanib with neoadjuvant chemotherapy (NACT) for epithelial ovarian cancer published in the Gynecologic Oncology